Nektar Therapeutics Faces Securities Class Action Over Failed Trial Disclosures
Law firm Bernstein Liebhard announces class action against $NKTR over alleged misrepresentations regarding Phase 2b trial results, affecting investors from February to December 2025.
PLUGSLNONKTRsecurities fraudclass action lawsuit
